Mozart Therapeutics Announces Poster Presentation at FOCIS 2023 Annual Meeting

SEATTLE, WA. May 25, 2023 — Mozart Therapeutics, a leading developer of therapeutic CD8 Treg Modulators for the treatment of autoimmune and inflammatory disease, today announced an upcoming presentation at the Federation of Clinical Immunology Societies Annual Meeting (FOCIS 2023) titled:

Pre-clinical Pharmacologic and Tolerability Characterization of MTX-101, a Novel KIRxCD8 Targeting Bispecific CD8 Treg Modulator (Abstract #1517124).

FOCIS 2023 is taking place in Boston on June 20-23, 2023.

About Mozart Therapeutics

Mozart Therapeutics is focused on developing disease-modifying therapies for autoimmune and inflammatory diseases that work by targeting a novel regulatory CD8 T regulatory cell network. The therapeutic focus of Mozart’s lead program is autoimmune mediated gastro-intestinal disorders. The company is headquartered in Seattle, WA. For more information visit www.mozart-tx.com and follow the company on LinkedIn @Mozart-tx.

Media Contact: 
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
206-769-9219